Claims for Patent: 10,265,401

Summary for Patent: 10,265,401

Title:	Stable subcutaneous protein formulations and uses thereof
Abstract:	The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
Inventor(s):	Desai; Manisha P (Wayne, NJ), Dahlheim; Charles E (Lawrenceville, NJ), Borsadia; Sunita (Plainsboro, NJ), Naringrekar; Vijay H (Princeton, NJ), Gandhi; Rajesh Babulal (Plainsboro, NJ), Nerurkar; Manoj (Bellandur, IN)
Assignee:	BRISTOL-MYERS SQUIBB COMPANY (Princeton, NJ)
Application Number:	15/066,480
Patent Claims:	1. A method for treating rheumatoid arthritis comprising administering to a subject in need thereof an effective amount of a stable formulation suitable for subcutaneous administration comprising the CTLA4Ig molecule having the amino acid sequence shown in SEQ ID NO:2 starting at methionine at position 27 or alanine at position 26 and ending at lysine at position 383 or glycine at position 382 in an amount of about 125 mg/ml, sucrose in an amount of about 170 mg/ml, at least one buffering agent, sterile water for injection and a surfactant, wherein the formulation has a pH range of from 6 to 7.8, and wherein the formulation is administered in a 1 ml volume. 2. A method for treating rheumatoid arthritis comprising administering to a subject in need thereof an effective amount of a stable formulation suitable for subcutaneous administration comprising the CTLA4Ig molecule having the amino acid sequence shown in SEQ ID NO:2 starting at methionine at position 27 or alanine at position 26 and ending at lysine at position 383 or glycine at position 382 in an amount of about 125 mg/ml, sucrose in an amount of about 170 mg/ml, at least one buffering agent, sterile water for injection and a surfactant, wherein the formulation has a pH range of from 6 to 7.8, and wherein the formulation is administered once a week in a 1 ml volume. 3. The method of claim 1 or 2 wherein the stable formulation suitable for subcutaneous administration is stable when stored at 2 to 8.degree. C. for at least 12 months. 4. The method of claim 1 or 2 wherein the stable formulation suitable for subcutaneous administration has an osmolality of from 700 mOsm/kgH2O to 800 mOsm/kgH2O. 5. The method of claim 1 or 2 wherein the stable formulation suitable for subcutaneous administration has a viscosity of from 9 to 20 mPas. 6. The method of claim 1 or 2, wherein the surfactant is selected from the group consisting of polysorbates, polysorbate 20, polysorbate 80, poloxamers, poloxamer 188, sorbitan esters, sorbitan derivatives, Triton, sodium laurel sulfate, sodium octyl glycoside, lauryl-sulfobetadine, myristyl-sulfobetadine, linoleyl-sulfobetadine, stearyl-sulfobetadine, lauryl-sarcosine, myristyl-sarcosine, linoleyl-sarcosine, stearyl-sarcosine, linoleyl-betaine, myristyl-betaine, cetyl-betaine, lauramidopropyl-betaine, cocamidopropyl-betaine, linoleamidopropyl-betaine, myristamidopropyl-betaine, palmidopropyl-betaine, isostearamidopropyl-betaine, lauroamidopropyl-dimethylamine, myristamidopropyl-dimethylamine, palmidopropyl-dimethylamine, isostearamidopropyl-dimethylamine, sodium methyl cocoyl-taurate, and disodium methyl oleyl-tauratem, polyethylene glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol. 7. The method of claim 6, wherein the surfactant is poloxamer 188. 8. The method of claim 1 or 2, wherein the buffering agent is selected from the group consisting of dibasic sodium phosphate anhydrous, monobasic sodium phosphate monohydrate, glycinate buffers, carbonate buffers, citrate buffers and combinations thereof. 9. The method of claim 8 wherein the buffering agent is in an amount of at least 10 mM phosphate buffer. 10. The method of claim 1 or 2, wherein the stable formulation suitable for subcutaneous administration further comprises a preservative. 11. The method of claim 10, wherein the preservative is selected from the group consisting of octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl alcolhol, benzyl alcohol, alkyl parabens, methyl paraben, propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol. 12. The method of claim 3, wherein the percentage of CTLA4Ig high molecular weight species in the stable formulation suitable for subcutaneous administration is less than about 25%. 13. The method of claim 3, wherein the percentage of CTLA4Ig high molecular weight species in the stable formulation suitable for subcutaneous administration is less than about 15%. 14. The method of claim 3, wherein the percentage of CTLA4Ig high molecular weight species in the stable formulation suitable for subcutaneous administration is less than about 10%. 15. The method of claim 3, wherein the percentage of CTLA4Ig high molecular weight species in the stable formulation suitable for subcutaneous administration is less than about 5%. 16. The method of claim 3, wherein the percentage of CTLA4Ig high molecular weight species in the stable formulation suitable for subcutaneous administration is less than about 3%.

Details for Patent 10,265,401

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2025-12-20